To examine the utility of our iGenSig-Rx method in modeling clinical trial datasets, we utilized multiple genomic datasets of clinical trials for HER2 targeted therapy in breast cancer patients, including CALGB 40601, ACOSOG Z1041, NOAH, and NSABP B-41. This evidence concerns the gene ERBB2 and breast carcinoma.